Further study of these mechanisms and drugs that target RAGE-mediated endocytosis of HMGB1 and its binding partners (e.g., C1q) may offer insight into approaches to regulating inflammatory responses in CKD and COVID-19. Here, AGER is linked to chronic kidney disease.